PWP
CTMX icon

Pursue Wealth Partners’s CytomX Therapeutics CTMX Stock Holding History

Pursue Wealth Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68K Hold
14,492
– – 0.04% 101
2025
Q4 		$62K Hold
14,492
– – 0.03% 104
2025
Q3 		$46.2K Hold
14,492
– – 0.03% 110
2025
Q2 		$32.9K Buy
+14,492
New +$23.4K 0.02% 110

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pursue Wealth Partners's CTMX Position: Q1 2026 in Review

Pursue Wealth Partners held its CytomX Therapeutics (CTMX) position steady in Q1 2026 at 14,492 shares worth $68K. The position accounts for 0.04% of the portfolio, ranked #101.

Pursue Wealth Partners first reported a position in CTMX in Q2 2025 and has held it in 4 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Pursue Wealth Partners held 14,492 shares of CytomX Therapeutics worth $68K as of Q1 2026.
  • Pursue Wealth Partners left its CytomX Therapeutics share count unchanged in Q1 2026.
  • CytomX Therapeutics made up 0.04% of Pursue Wealth Partners's portfolio in Q1 2026, its #101 holding.
  • Pursue Wealth Partners first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Pursue Wealth Partners's 13F filing for Q1 2026, filed 8 Apr 2026.